Compass Therapeutics (NASDAQ:CMPX) Sets New 52-Week High on Analyst Upgrade

Compass Therapeutics, Inc. (NASDAQ:CMPX - Get Free Report)'s share price reached a new 52-week high during trading on Monday after Jefferies Financial Group raised their price target on the stock from $7.00 to $8.00. Jefferies Financial Group currently has a buy rating on the stock. Compass Therapeutics traded as high as $3.95 and last traded at $3.94, with a volume of 359782 shares changing hands. The stock had previously closed at $3.50.

Other equities research analysts have also issued research reports about the stock. Leerink Partnrs lowered shares of Compass Therapeutics from a "strong-buy" rating to a "hold" rating in a research note on Friday, November 15th. D. Boral Capital restated a "buy" rating and set a $32.00 price objective on shares of Compass Therapeutics in a research note on Wednesday, January 8th. Leerink Partners lowered Compass Therapeutics from an "outperform" rating to a "market perform" rating and decreased their target price for the stock from $5.00 to $4.00 in a research report on Friday, November 15th. Finally, HC Wainwright reissued a "buy" rating and set a $10.00 price target on shares of Compass Therapeutics in a research report on Wednesday, January 8th. Two research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus price target of $11.17.

Hedge Funds Weigh In On Compass Therapeutics

Several institutional investors have recently made changes to their positions in the stock. Cubist Systematic Strategies LLC bought a new stake in shares of Compass Therapeutics in the 2nd quarter worth approximately $41,000. SG Americas Securities LLC lifted its stake in Compass Therapeutics by 16.6% in the third quarter. SG Americas Securities LLC now owns 38,665 shares of the company's stock valued at $71,000 after buying an additional 5,515 shares during the last quarter. Rovin Capital UT ADV acquired a new position in shares of Compass Therapeutics during the third quarter valued at $25,000. Intech Investment Management LLC acquired a new position in shares of Compass Therapeutics during the third quarter valued at $30,000. Finally, The Manufacturers Life Insurance Company bought a new position in shares of Compass Therapeutics during the third quarter worth about $79,000. 68.43% of the stock is owned by institutional investors.

Compass Therapeutics Stock Performance

The firm has a market cap of $468.49 million, a price-to-earnings ratio of -9.20 and a beta of 1.17. The stock's fifty day moving average is $2.20 and its two-hundred day moving average is $1.77.

Compass Therapeutics (NASDAQ:CMPX - Get Free Report) last announced its quarterly earnings results on Tuesday, November 12th. The company reported ($0.08) EPS for the quarter, beating the consensus estimate of ($0.11) by $0.03. Sell-side analysts predict that Compass Therapeutics, Inc. will post -0.35 earnings per share for the current year.

About Compass Therapeutics

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.